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Background: Nausea and vomiting of pregnancy (NVP) is a common condition. The objective of this study was to
evaluate the association between response to antiemetics in the treatment of NVP and genetic polymorphisms in
the serotonin receptor subunit genes HTR3A and HTR3B.
Methods: Pregnant women ≥18 years of age with NVP starting antiemetic therapy with promethazine,
prochlorperazine, metoclopramide, or ondansetron at ≤ 16 weeks gestational age were eligible. The study recruited
29 women with complete data and sampling who returned for their one week follow-up and were genotyped for
HTR3A and HTR3B polymorphisms. Severity of NVP was captured (using Pregnancy Unique Quantification of Emesis
(PUQE) and Quality of Life (QOL) tools) upon enrollment and after one week of antiemetic therapy. These measures
were correlated with pharmacogenetic variability.
Results: Subjects with genotype associated with high serotonin affinity of the 5-HT3B receptor (rs1176744, CC)
required more antiemetic medications (p < 0.001) than other subjects. Those with genotypes associated with
increased expression of the 5-HT3A receptor subunit (rs1062613, CT or TT) had worse final PUQE scores (p = 0.01)
than other subjects while rs3782025 variants carriers had significantly better initial (p = 0.02) and final (p = 0.02)
PUQE scores than other subjects.
Conclusions: HTR3B and HTR3A gene variants may contribute to variability in response to antiemetic therapy for NVP.
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Nausea and vomiting of pregnancy (NVP) affects up to
80% of all pregnant women [1-3]. Although NVP is most
common during the first trimester of pregnancy, as
many as 20% of pregnant women are affected beyond
12 weeks of gestation and throughout the day (vs. isolated
to the morning hours). Of the women affected, 1 to 3% ex-
perience a severe form of NVP called hyperemesis
gravidarum (HG) which includes weight loss, dehydration,
and electrolyte imbalances. In mild cases, NVP causes
discomfort and inconvenience; however, HG can pose* Correspondence: dahaas@iupui.edu
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reproduction in any medium, provided the orsignificant risks to the health of the pregnant woman and
the fetus—often necessitating hospitalization [4]. Even the
milder cases of NVP can have a significant impact on the
quality of a woman’s life and contribute significantly to
health care costs and time lost from work [2,3,5]. Termin-
ation of otherwise wanted pregnancies has been reported
in women suffering from severe, prolonged NVP [6].
However, because NVP is rarely life-threatening, the goal
of pharmacologic treatment is typically improvement in
the quality of life for affected pregnant women [7].
Several dopamine antagonist antiemetics commonly
used in pregnancy also act as weak serotonin receptor an-
tagonists. These include promethazine, prochlorperazine,
and metoclopramide. Additionally, the 5-HT3 receptor
antagonist ondansetron is an often used antiemetic in
pregnancy. These antiemetics have been studied extensivelyral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ever, response to these medications in the treatment of
NVP is highly variable [7,11-13]. While pharmacologic
intervention may ameliorate symptoms in many women,
some women improve dramatically while others continue
to experience severe NVP despite treatment. As such,
pharmacogenetic polymorphisms become an important
consideration in evaluating variability in responsiveness to
pharmacologic intervention. Many antiemetics are sub-
strates for serotonin receptors and transporters—which
are known to have clinically relevant genetic polymor-
phisms. Previous studies have shown that variations in the
HTR3B gene predict the efficacy of antiemetics in cancer
patients [14] and the occurrence of selective serotonin
reuptake inhibitor (SSRI)-induced nausea [15]. However,
there have been limited studies which have investigated
the effects of the serotonin receptor gene polymorphisms
on the efficacy of antiemetics used in the treatment of
NVP [16].
The objective of this study was to evaluate the role of
serotonin receptor subunit HTR3A and HTR3B genotype
with NVP severity and antiemetic efficacy.
Methods
Study population
Pregnant women ≥18 years of age diagnosed with NVP
during the first trimester of pregnancy were recruited
from obstetric clinics associated with Indiana University
School of Medicine. Subjects had to be experiencing
NVP for at least one week. Subjects were recruited when
presenting for therapy for NVP to either an acute care
area or prenatal clinic. Informed consent was obtained
from all subjects. Women with multiple gestations or
beyond 16 weeks gestation were excluded. Women with
a history of hypertension, epilepsy, or diabetes; history of
hepatitis or gastrointestinal disorders that might mani-
fest as nausea or vomiting; history of hyperthyroidism
or current hyperthyroidism; or who were unwilling to
complete a follow-up visit within one week or to complete
NVP severity surveys over the telephone were excluded
from the study.
Subject demographics, gestational age at presentation,
and the medications prescribed by the provider were all
recorded. As this was not a treatment trial, the drug
therapy choice was left to the treating provider. The
study was approved by the Indiana University Purdue
University-Indianapolis Institutional Review Board.
Sample collection and processing
A collection of up to 10 mL of whole blood in a K2EDTA
vacutainer was obtained for DNA sampling and phar-
macogenetic testing upon enrollment in the study. Sam-
ples were stored at −80°C until DNA isolation was
completed. If a whole blood sample could not be obtainedfrom the enrolled patient for any reason a saliva sample
was taken for DNA sampling and pharmacogenetic testing
using an Oragene® saliva kit collection.
DNA was extracted from whole blood samples using the
QIAamp® DNA mini kits (Qiagen Inc., Valencia, CA).
Manufacturer spin protocol instructions were followed.
Isolation of DNA from saliva samples was done following
the manufacturer specified protocol “Laboratory Protocol
for Manual Purification of DNA from Oragene® DNA/Sal-
iva.” All DNA samples were transferred into cryovials and
stored at −80°C until quantification. Concentration of
double-stranded DNA in our samples was determined
using a Quant-iT dsDNA Broad Range or High Sensitivity
Assay Kit and Qubit Flourometer (Invitrogen, Carlsbad,
California.)
Pharmacogenetics
Subject samples were genotyped for the following sero-
tonin receptor gene SNPs: HTR3B nonsynonymous SNP
Tyr129Ser (rs1176744); HTR3B intronic SNP (rs3782025);
HTR3B deletion −104_-102delAGA (also known by the
alias −102_-100delAAG) (rs3831455); and HTR3A 5’-UTR
SNP Pro16Ser (rs1062613). Genotyping was done using
predesigned or custom commercially available Taqman
Real-Time polymerase chain reaction (PCR) assays follow-
ing manufacturer published methods (Applied Biosystems,
Darmstadt, Germany). Although our genes of interest
encode hundreds of amino acids, we thought it most ap-
propriate in this pilot study to select several SNPs that
had previously been cited as having functional and/or clin-
ical significance in afflictions largely characterized by nau-
sea and vomiting. Additionally, these SNPs were chosen
based on commercial availability and population preva-
lence. Based on the available population prevalence data,
all chosen SNPs showed a minor allele frequency of at
least 5% in all ethnic groups that participated in this study.
For instance the minor allele frequency in European and
African populations for rs1176744 are 0.29 and 0.43, re-
spectively. Rs 3782025 has minor allele frequencies of 0.46
and 0.40 in the same populations respectively and rs
1062613 has minor allele frequencies of 0.21 and 0.49 in
the same populations, respectively (www.ncbi.nlm.nih.gov
accessed 8/8/2012).
NVP severity tools
The Motherisk Pregnancy Unique Quantification of
Emesis (PUQE) score, a validated scoring tool (Table 1)
to quantify the severity of NVP [17,18], was used to as-
sess self-perceived symptom severity and well-being.
Based on quantification of the three physical symptoms
of NVP, PUQE closely correlates with the Rhodes’ Index
score, another validated but much more complex tool.
To further assess specific ways in which NVP impacts
women’s lives, a brief, six-question Likert-scale survey
Table 1 Motherisk Pregnancy Unique Quantification of
Emesis (PUQE) scoring tool
PUQE questions Score
1. In the last 24 hours, for how long have you felt nauseated or
sick to your stomach?
•Not at all (n = 1)
•1 hour or less (n = 2)
•2 to 3 hours (n = 3)
•4 to 6 hours (n = 4)
•More than 6 hours (n = 5)
2. In the last 24 hours, how many times have you vomited or
thrown up?
•7 or more times (n = 5)
•5 to 6 times (n = 4)
•3 to 4 times (n = 3)
•1 to 2 times (n = 2)
•I did not throw up (n = 1)
3. In the last 24 hours, how many times have you had retching
or dry heaves without bringing anything up?
•No times (n = 1)
•1 to 2 times (n = 2)
•3 to 4 times (n = 3)
•5 to 6 times (n = 4)•7 or more times (n = 5)
Total Score
This survey scoring tool was administered at baseline and after a week
of therapy.
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istered to study participants (Table 2). PUQE scores as
well as QOL scores were collected on entry into the
study and one-week after starting antiemetic therapy
with promethazine, ondansetron, prochlorperazine, or
metoclopramide. The patient PUQE and QOL scores
were collected by telephone for patients unable to return
for the one-week follow-up visit. A one-week follow-up
was selected to try to capture the effects of the medica-
tions prescribed due to the fact that the condition of
NVP is one that over time may resolve itself. If treat-
ment with antiemetic medications had been started prior
to enrollment, the subject was asked to provide a base-
line PUQE score estimate retrospectively to the timeTable 2 Impact of NVP on Normal Functioning Quality of Life
1. My NVP has limited me in doing my work or other daily activities in the la
2. My NVP has limited me in pursuing my hobbies or other leisure time activ
2. My NVP has prevented me from caring for my other children________ I h
4. My NVP has prevented me from eating in the last week.
5. My NVP has prevented me from taking prenatal vitamins in the last week.
6. My NVP has negatively affected my relationship with my partner in the las
Each of the ratings are totaled up for a total QOL score. NVP = Nausea and vomitingtreatment was initiated, then current PUQE score on
day of enrollment and a follow-up PUQE score one week
after enrollment. For these subjects, the baseline PUQE
and QOL were used as the Initial PUQE and QOL
scores. Final PUQE and QOL scores were taken at the
one-week follow-up and a change in PUQE and QOL
(Δ) were calculated by subtracting the initial score from
the final score. For both the PUQE and QOL tools,
higher scores indicate more negative symptoms and
impact of NVP for the subject. The number of drugs
prescribed for the women over the course of their treat-
ment for NVP was also used as a surrogate for disease
severity as most obstetric providers begin by prescribing
one drug but prescribe more than one for recalcitrant or
very severe cases.
Statistical analysis
All data were analyzed using SPSS-PASW Statistics v.18
(SPSS, Inc., Chicago, IL). Descriptive summary statistics
were generated for maternal characteristics and the spe-
cific serotonin receptor genotype. In each case, the wild
type alleles were compared to subjects having at least
one variant allele. Linear regression modeling compared
the correlation of genotype to the PUQE and QOL
scores and number of drugs prescribed. Comparison of
categorical variables was performed using chi-square
testing. Continuous variables were compared using
ANOVA testing or Mann–Whitney U or Kruskal Wallis
tests for nonparametric data.
Results
Twenty-nine women with NVP who had complete data
and sampling and returned for their one week follow-up
were included in this study. The mean age of subjects
was 26.2 ± 5.3 years. The mean gestational age at presen-
tation was 12.0 ± 1.4 weeks. The ethnic distribution of
the subjects was 9 (32.1%) Caucasian, 17 (60.7%)
African-American, and 2 (7.1%) Hispanic. Medications
prescribed were promethazine, metoclopramide, prochlor-
perazine, and ondansetron. Some women 15/29 (51.7%)
received more than one drug to control symptoms during
the treatment period. No participants were using acupres-
sure or were using non-prescription treatments such as(QOL) survey tool
Not at all A little Quite a bit Very much
st week. 1 2 3 4
ities in the last week. 1 2 3 4
ave no other children 1 2 3 4
1 2 3 4
1 2 3 4
t week. 1 2 3 4
of pregnancy.
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though these were not specifically prohibited. Table 3
displays the NVP severity score summary for the study
cohort. One woman’s DNA was unusable for genotyping,
leaving 28 women for genetic analysis.
The serotonin receptor genotypes were obtained for all
included subjects. For rs1176744, subjects were catego-
rized as having the genotype AA (wild-type, 6, 21.4%), AC
(heterozygous, n = 16, 57.1%), or CC (homozygous variant,
n = 6, 21.4%). For rs3782025, subjects were homozygous
wild type (AA, n = 3, 11.5%) or heterozygous (AG, n = 14,
23, 88.5%). For rs3831455, 22 subjects (84.6%) were homo-
zygous wild type and 4 (15.4%) carried the deletion allele.
For rs1062613 SNP, 10 (41.7%) were homozygous wild
type (CC), 9 (37.5%) were heterozygous (CT), and 5
(20.8%) were homozygous variant alleles (TT).
Figures 1 and 2 display the polymorphisms’ impact on
PUQE scores (Figure 1) and QOL scores (Figure 2). For
the rs3782025 polymorphism, the initial and final PUQE
scores were significantly better for carriers of a variant
allele (p = 0.02 for both comparisons). The final PUQE
score was significantly worse for carriers of the rs1062613
variant (p = 0.01). There were trends toward significant
differences for rs3782025 final QOL scores (p = 0.08),
rs3831455 final PUQE scores (p = 0.07), and rs1062613
initial QOL scores (p = 0.05).
Table 4 displays the difference in the mean number of
drugs given to control NVP symptoms for the women with
the different genotypes. Women with variant rs1176744 ge-
notypes required treatment with a greater number of
antiemetic drugs (p < 0.001). There were no significant dif-
ferences in the percent of women who needed more than
one drug to control symptom in any of the SNP compari-
son groups (data not shown).Discussion
Although the complete pathogenesis of NVP is un-
known, serotonin is a key mediator in inducing nauseaTable 3 Summary of NVP severity parameters for the
study population
Variable Mean ± Standard
deviation
Median Range
Initial PUQE 10.7 ± 3.4 12 3-15
Final PUQE 7.0 ± 3.5 6 2-15
Change in PUQE 4.7 ± 2.8 5 −2-9
Initial QOL 16.7 ± 4.2 17 8-23
Final QOL 11.9 ± 5.7 9 6-24
Change in QOL 5.3 ± 6.3 3 −4-16
Number of drugs
given
1.6 ± 0.7 2 1-3
PUQE Pregnancy Unique Quantification of Emesis score. QOL Quality of
Life score.and vomiting through a mechanism in which 5-HT acts
on its receptor in the gastrointestinal tract, 5-HT3. This
receptor relays information to the central nervous sys-
tem through depolarization of vagal afferent nerves and
the vagus nerve. This signal is thought to initiate the
vomiting reflex [19]. Excess serotonin is released by
small intestinal enterochromaffin cells in response to
drugs such as chemotherapeutic agents [20]. 5-HT3 an-
tagonists are a class of medications that act at the 5-HT3
receptor, preventing serotonin from binding and thereby
preventing vagal afferent stimulation and induction of
the vomiting reflex. Many 5-HT3 antagonists are anti-
emetics and are used in the prevention and treatment of
nausea and vomiting.
The ligand-gated ion channel serotonin receptor type
3 (5-HT3) is found in the autonomic, enteric, and sen-
sory nervous systems [21]. Although five subunits of 5-
HT3 have been identified in humans (5-HT3A-3E), 5-HT
3A is the only subunit that is capable of forming homo-
oligomeric receptor complexes that are functional. All
other subunits are able to form only heteropentameric
receptor complexes with 5-HT3A [22]. Therefore, 5-HT
3A is a consistently important subunit and 5-HT3B has
previously been shown to be a major factor in HTR3
function [23]. Additionally, 5-HT3A and 5-HT3B are best
characterized and both functional and clinically relevant
genetic polymorphisms exist in the genes of these sub-
units so we focused on these relevant polymorphism. To
our knowledge, only one other study has examined the
relationship between NVP and 5-HT3 receptor genotype.
This study focused largely on a different set of genetic
polymorphisms and found a weak association between
NVP and two HTR3C variants but did not find any asso-
ciation when examining two HTR3A variants, including
one that was also tested in this study [16].
A variant form of the 5-HT3B receptor (rs1176744
variants) has been shown to exhibit a substantially in-
creased maximum response (7-fold increased mean open
time) to serotonin compared to the wild type form [24].
While Tremblay et al. [14] found that this variant was not
predictive of nausea and vomiting incidence in cancer pa-
tients, Sugai et al. [15] found this variant to be predictive of
higher nausea incidence in a paroxetine-induced nausea
setting. Our results indicate that this variant appears to
contribute to decreased response to antiemetic therapy for
NVP as homozygous variant subjects were prescribed more
antiemetic medications to control symptoms than those
with at least one wild type allele. These results suggest that
women with this particular homozygous mutation in
HTR3B may have more recalcitrant NVP. As such, homo-
zygous variant patients may not be receiving high enough
dosing of antiemetic therapy to inhibit serotonin binding at
the 5-HT3 receptor target due to the increased affinity of
the receptor for serotonin in these subjects.
Figure 1 Comparison of PUQE scores by serotonin receptor genotype. Initial and final scores and the change (Δ) in the score are reported
for 4 different single nucleotide polymorphisms. Given as Mean ± Standard Deviation, Significance; *, P≤ 0.02.
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shown to have functional significance. This nonsense
mutation occurs in the upstream open reading frame of
HTR3A. Luciferase reporter constructs showed that
presence of the variant allele results in significant in-
creases in expression [25]. Despite this, Kaiser et al. [26],
Sugai at al. [15], and Goeke et al. [16] found that HTR3A
polymorphisms were not good predictors of antiemeticFigure 2 Comparison of QOL scores by Serotonin receptor genotype.
for 4 different single nucleotide polymorphisms. Given as Mean ± Standardtreatment in cancer patients, SSRI-induced nausea, or
NVP, respectively. However, our data showed that des-
pite statistically similar initial PUQE scores, carriers of a
variant rs1062613 allele had significantly worse final
PUQE scores. We also found that there is a trend toward
significant differences in initial QOL scores with variant
carriers having worse initial QOL compared to other pa-
tients. This discrepancy could be caused by medicationInitial and final scores and the change (Δ) in the score are reported
Deviation.





Mean ± Std Dev
wild type group




rs1176744 1.0 ± 0.0 1.7 ± 0.7 <0.001
(6 wild type, 22
variant)
rs3782025 1.3 ± 0.6 1.6 ± 0.6 0.50
(3 wild type, 23
variant)
rs3831455 1.6 ± 0.6 1.5 ± 1.0 0.73
(22 wild type, 4
variant)
rs1062613 1.5 ± 0.5 1.6 ± 0.8 0.80
(10 wild type, 14
variant)
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gest that patients who carry at least one variant allele
may not be receiving a sufficient dose of antiemetics to
antagonize the increased receptors that may be expressed.
Previous work has found that the 3 base pair inser-
tion/deletion polymorphism, rs3831455, in the promoter
region of the HTR3B gene was found to significantly as-
sociate with incidence of nausea and vomiting caused by
chemotherapy [14]. This HTR3B promoter deletion, or
variant, was also found to change the mRNA structure
and was suggested to have an effect on translation effi-
ciency [27] and nuclear protein binding [28]. Our results
indicated a trend for this insertion/deletion polymorph-
ism with worse final PUQE scores in patients carrying a
variant allele. This could be due to increased translation
and expression in those carrying the variant which could
lead to insufficient antiemetic dosing to control symptoms.
Although the functional consequences of the HTR3B
variant rs3782025 are unclear this polymorphism has
been associated with vulnerability to alcohol use disor-
ders (AUD), another condition that has been suggested
to be affected by 5-HT dysfunction [29]. We found this
polymorphism to be significantly associated with both
initial and final PUQE scores, with variant carriers
having better scores. Carriers of this variant also trended
towards better final QOL scores. These data suggest that
carrying a variant rs3782025 allele may be protective
against NVP, as baseline severity and outcome are im-
proved in these women.
Conclusions
For patients with significant emesis this may be an
important step in improving treatment strategies. If these
findings are confirmed in larger studies, it is possible that
women with certain serotonin receptor genotypes may be
better suited for one antiemetic drug versus another ormay require a higher starting dose of drug. Alternate ther-
apy may be prescribed based on genotype or patients may
start therapy on multiple drugs rather than monotherapy.
This could provide significant time and money savings as
well as provide much needed symptom relief and may
improve safety for both the mother and the fetus.
Our study was limited by small sample size. This pilot
study was not powered to find differences in secondary
outcomes, however the trends seen here will inform
samples size for follow-up studies. There was also a po-
tential for recall bias, however validated measures were
used, increasing the validity of the results. Another limi-
tation is that the study did not mandate a specific NVP
treatment algorithm and did not direct physician’s pre-
scribing patterns in any way. As such, while the number
of antiemetic medications given to each subject was used
as a surrogate for severity of NVP, it is confounded by
variability in provider practice. Because standard practice
is to start with one drug and add more to obtain symp-
tom control we believe that this is a reasonable surro-
gate of symptom severity. We also did not measure
treatment adherence. These results need to be validated
in a larger cohort. Additionally, ability to perform sub-
group analyses of treatment groups by increasing sample
size may improve the ability to build a pharmacogenetic
treatment model, which could be used to guide clinical
practice. A prospective treatment trial based on geno-
type and examining an expanded serotonin receptor
pathway genetic analysis is currently being planned.
In conclusion, this pilot study of pharmacogenetic pre-
dictors of NVP therapy response demonstrates that
genotype for serotonin receptor subunits 5-HT3A and 5-
HT3B may play a role in disease severity and response.
There is a need for more pharmacogenetic studies in
pregnancy, particularly for conditions necessitating drug
therapy such as NVP. As pharmacogenetic studies
emerge in obstetric conditions such as NVP, the poten-
tial for individualized pharmacotherapy at the outset of
treatment may be realized.
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